Published in Front Oncol on July 08, 2015
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810
ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med (2016) 1.41
Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes. Oncotarget (2016) 0.81
Regulation of prostate cancer progression by the tumor microenvironment. Cancer Lett (2016) 0.81
A primer on tumour immunology and prostate cancer immunotherapy. Can Urol Assoc J (2016) 0.79
Vitamin D and Immune Response: Implications for Prostate Cancer in African Americans. Front Immunol (2016) 0.78
From Inflammation to Prostate Cancer: The Role of Inflammasomes. Adv Urol (2016) 0.76
Racial disparities in prostate cancer: a molecular perspective. Front Biosci (Landmark Ed) (2017) 0.75
Immunotherapy in metastatic prostate cancer. Indian J Urol (2016) 0.75
Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice. PLoS One (2016) 0.75
Blood-based gene expression profiling in castrate-resistant prostate cancer. BMC Med (2015) 0.75
The Relationship between Obesity, Prostate Tumor Infiltrating Lymphocytes and Macrophages, and Biochemical Failure. PLoS One (2016) 0.75
Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome. Nucleic Acids Res (2016) 0.75
Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer. Int J Mol Sci (2017) 0.75
Inflammation in Prostatic Hyperplasia and Carcinoma-Basic Scientific Approach. Front Oncol (2017) 0.75
Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. Oncotarget (2017) 0.75
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Cancer-related inflammation. Nature (2008) 34.21
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2012) 15.83
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
International trends and patterns of prostate cancer incidence and mortality. Int J Cancer (2000) 3.73
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol (2000) 3.48
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol (2013) 2.87
Cancer epidemiology in the last century and the next decade. Nature (2001) 2.72
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer Immunol Immunother (2012) 2.22
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
Epidemiologic association between prostatitis and prostate cancer. Urology (2002) 2.05
Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science (2008) 1.99
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer (2014) 1.93
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature (2014) 1.88
Tumor promotion via injury- and death-induced inflammation. Immunity (2011) 1.81
Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer (2013) 1.66
A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med (2006) 1.66
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer Prostatic Dis (2012) 1.53
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013) 1.51
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods (2009) 1.48
The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol (2006) 1.45
Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A (2013) 1.43
High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology (1999) 1.42
Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature (2015) 1.42
Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol (2006) 1.36
Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int (2010) 1.29
Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer (2009) 1.24
Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia. Am J Pathol (2010) 1.23
Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol (2010) 1.19
Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis (2011) 1.17
Acute bacterial inflammation of the mouse prostate. Prostate (2011) 1.16
Prostatitis as a risk factor for prostate cancer. Epidemiology (2004) 1.14
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother (2014) 1.13
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer (2014) 1.12
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer (2009) 1.09
A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. Prostate (2013) 1.09
Inflammation and prostate carcinogenesis. Int J Urol (2012) 1.07
Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res (2013) 1.04
Inflammation and prostate cancer. Future Oncol (2008) 1.04
Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.03
Tumor infiltrating B-cells are increased in prostate cancer tissue. J Transl Med (2014) 1.02
Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci U S A (2014) 1.01
Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother (2014) 1.00
The role of prostatitis in prostate cancer: meta-analysis. PLoS One (2013) 0.98
Prostate cancer risk-associated genetic markers and their potential clinical utility. Asian J Androl (2013) 0.97
Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res (2014) 0.96
Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate (2009) 0.95
Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res (2011) 0.95
Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice. Cancer Prev Res (Phila) (2012) 0.93
Prostate cancer vaccines in combination with additional treatment modalities. Immunol Res (2014) 0.93
The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. Biomed Res Int (2014) 0.92
Co-inoculation of prostate cancer cells with U937 enhances tumor growth and angiogenesis in vivo. J Cell Biochem (2008) 0.91
Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res (2012) 0.91
Exploiting synergy: immune-based combinations in the treatment of prostate cancer. Front Oncol (2014) 0.91
An IKKα-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev (2013) 0.90
Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol (2014) 0.89
Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS (2012) 0.89
Targeting the androgen receptor in prostate cancer. Expert Opin Pharmacother (2014) 0.89
Persistent inflammation leads to proliferative neoplasia and loss of smooth muscle cells in a prostate tumor model. Neoplasia (2011) 0.89
Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy. Am J Pathol (2009) 0.88
Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. Int Urol Nephrol (2014) 0.88
Topographic and quantitative relationship between prostate inflammation, proliferative inflammatory atrophy and low-grade prostate intraepithelial neoplasia: a biopsy study in chronic prostatitis patients. Int J Oncol (2012) 0.87
Combined treatment targeting HIF-1α and Stat3 is a potent strategy for prostate cancer therapy. Prostate (2011) 0.87
The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer. Res Rep Urol (2012) 0.86
Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue. APMIS (2010) 0.86
Chronic asymptomatic inflammation of the prostate type IV and carcinoma of the prostate: is there a correlation? Scand J Urol (2012) 0.84
Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? Semin Oncol (2013) 0.84
Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. Pathobiology (2013) 0.84
Mast cells as a potential prognostic marker in prostate cancer. Dis Markers (2013) 0.84
CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Res (2015) 0.83
The evolving role of immunotherapy in prostate cancer. Ann Oncol (2012) 0.82
Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer. Prostate (2014) 0.80
Does an inflammatory pattern at primary biopsy suggest a lower risk for prostate cancer at repeated saturation prostate biopsy? Urol Int (2011) 0.79
The role of prostatic inflammation biomarkers in the diagnosis of prostate diseases. Clin Biochem (2014) 0.79
Does absolute neutrophil count predict high tumor grade in African-American men with prostate cancer? Prostate (2011) 0.78
Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature. Invest New Drugs (2014) 0.77
Destructive impact of T-lymphocytes, NK and Mast cells on basal cell layers: implications for tumor invasion. BMC Cancer (2013) 0.77